{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:55:54Z","timestamp":1791237354298,"version":"4.1.0"},"reference-count":39,"publisher":"Radiation Research Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiation Research"],"published-print":{"date-parts":[[2026,3,25]]},"abstract":"<jats:p>Enhanced DNA repair is a common mechanism of radiation resistance. XRD-0394, a novel small molecule dual inhibitor of ataxia telangiectasia mutated (ATM) kinase and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PKcs), may sensitize tumor cells to killing by external beam radiation therapy (EBRT) or radiopharmaceutical therapy (RPT). DNA damage response inhibition and increased cytotoxicity were observed in Myc-CaP prostate cancer tumor cells after irradiation 1 XRD-0394 as indicated by the inhibition of radiation- induced phosphorylation of KAP1, p53, and H2A.X and decreased clonogenic potential. In mice bearing the FaDu head and neck squamous cell carcinoma (HNSCC) xenograft tumor model, the combination of irradiation or 177Lu-NM600 1 XRD-0394 improved tumor response and overall survival compared to monotherapy controls. Increased expression of type I interferon response genes was observed after irradiation 1 XRD-0394 compared to irradiation alone, suggesting that XRD-0394 may also accentuate the immunogenic effects of radiation on tumor cells. Further investigation is warranted into treatment approaches that combine radiopharmaceutical therapies, DNA repair inhibitors, and immunotherapies.<\/jats:p>","DOI":"10.1667\/rade-25-00203.1","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T13:46:33Z","timestamp":1775655993000},"page":"459-471","source":"Crossref","is-referenced-by-count":0,"title":["Enhanced Response to Radiopharmaceutical Therapy in Preclinical Tumor Models with XRD-0394, a Dual Inhibitor of ATM Kinase and DNA-PKcs"],"prefix":"10.1667","volume":"205","author":[{"given":"Caroline P.","family":"Kerr","sequence":"first","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Jong","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro J.","family":"O\u00f1ate","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohyun","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Medical Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hansel Comas","family":"Rojas","sequence":"additional","affiliation":[{"name":"Department of Medical Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Hyun","sequence":"additional","affiliation":[{"name":"Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina A.","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Department of Medical Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malick Bio","family":"Idrissou","sequence":"additional","affiliation":[{"name":"Department of Medical Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Mahfuzur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sheehan-Klenk","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin C.","family":"Jagodinsky","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Nystuen","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke M.","family":"Zangl","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly N.","family":"Pinchuk","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KyungMann","family":"Kim","sequence":"additional","affiliation":[{"name":"Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinier","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Department of Medical Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Bednarz","sequence":"additional","affiliation":[{"name":"Department of Medical Physics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamey P.","family":"Weichert","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Kastan","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tona M.","family":"Gilmer","sequence":"additional","affiliation":[{"name":"XRad Therapeutics, Orlando, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Human Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1243","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"G Zhou, Z Liu, JN Myers,  \"J Cell Biochem.\"  117, \"TP53 Mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response.\" 2682 (2016)","DOI":"10.1002\/jcb.25592"},{"key":"3","doi-asserted-by":"crossref","unstructured":"M-KND Hutchinson, M Mierzwa, NJ D'Silva,  \"Oncogene.\"  39, \"Radiation resistance in head and neck squamous cell carcinoma: dire need for an appropriate sensitizer.\" 3638 (2020)","DOI":"10.1038\/s41388-020-1250-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"L Gong, Y Zhang, C Liu, et al.  \"Int J Nanomedicine.\"  16, \"Application of radiosensitizers in cancer radiotherapy.\" 1083 (2021)","DOI":"10.2147\/IJN.S290438"},{"key":"5","doi-asserted-by":"crossref","unstructured":"RM Samstein  and N Riaz  \"Adv Radiat Oncol.\"  3, \"The DNA damage response in immunotherapy and radiation.\" 527 (2018)","DOI":"10.1016\/j.adro.2018.08.017"},{"key":"6","doi-asserted-by":"crossref","unstructured":"H Obata, M Ogawa, MR Zalutsky,  \"Pharmaceutics.\"  15, \"DNA repair inhibitors: Potential targets and partners for targeted radionuclide therapy.\" 1926 (2023)","DOI":"10.3390\/pharmaceutics15071926"},{"key":"7","doi-asserted-by":"crossref","unstructured":"G. Sgouros,  \"Health Phys.\"  116, \"Radiopharmaceutical therapy.\" 175 (2019)","DOI":"10.1097\/HP.0000000000001000"},{"key":"8","doi-asserted-by":"crossref","unstructured":"O Sartor, J De Bono, KN Chi, et al.  \"N Engl J Med.\"  385, \"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer.\" 1091 (2021)","DOI":"10.1056\/NEJMoa2107322"},{"key":"9","doi-asserted-by":"crossref","unstructured":"J Strosberg, G El-Haddad, E Wolin, et al.  \"N Engl J Med.\"  376, \"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors.\" 125 (2017)","DOI":"10.1056\/NEJMoa1607427"},{"key":"10","doi-asserted-by":"crossref","unstructured":"B Xu, L Tao, J Sun, et al.  \"Apoptosis.\"  30, \"DNA damage repair inhibitors boost targeted radionuclide therapy and immunotherapy of prostate cancer.\" 2238 (2025)","DOI":"10.1007\/s10495-025-02136-7"},{"key":"11","doi-asserted-by":"crossref","unstructured":"B Perez, R Aljumaily, TU Marron, et al.  \"ESMO Open.\"  9, \"Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.\" 102217 (2024)","DOI":"10.1016\/j.esmoop.2023.102217"},{"key":"12","doi-asserted-by":"crossref","unstructured":"TM Gilmer, C-H Lai, K Guo, et al.  \"Mol Cancer Ther.\"  23, \"A novel dual ATM\/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors.\" 751 (2024)","DOI":"10.1158\/1535-7163.MCT-23-0890"},{"key":"14","doi-asserted-by":"crossref","unstructured":"HP Doub, A Bolliger, FW Hartman,  \"Radiology.\"  8, \"The selative sensitivity of the kidney to irradiation.\" 142 (1927)","DOI":"10.1148\/8.2.142"},{"key":"15","doi-asserted-by":"crossref","unstructured":"JJ Grudzinski, R Hernandez, I Marsh, et al.  \"J Nucl Med.\"  60, \"Preclinical cCharacterization of (86\/90)Y-NM600 in a variety of murine and human cancer tumor models.\" 1622 (2019)","DOI":"10.2967\/jnumed.118.224808"},{"key":"16","doi-asserted-by":"crossref","unstructured":"R Hernandez, KL Walker, JJ Grudzinski, et al.  \"Commun Biol.\"  2, \"90)Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin's lymphoma.\" 79 (2019)","DOI":"10.1038\/s42003-019-0327-4"},{"key":"18","doi-asserted-by":"crossref","unstructured":"R Hernandez, JJ Grudzinski, E Aluicio-Sarduy, et al.  \"J Nucl Med.\"  61, \"Lu-NM600 targeted radionuclide therapy extends survival in syngeneic murine models of triple-negative breast cancer.\" 1187 (177)","DOI":"10.2967\/jnumed.119.236265"},{"key":"19","doi-asserted-by":"crossref","unstructured":"CP Kerr, J Sheehan-Klenk, JJ Grudzinski, et al.  \"Cancer Immunol Res.\"  13, \"The effects of clinically relevant radionuclides on the activation of a type I interferon response correlate with radionuclide half-life and linear energy transfer and influence radiopharmaceutical antitumor efficacy.\" 1190 (2025)","DOI":"10.1158\/2326-6066.CIR-24-1191"},{"key":"21","doi-asserted-by":"crossref","unstructured":"WJ Jin, AK Erbe, CN Schwarz, et al.  \"Front Immunol.\"  11, \"Tumor-specific antibody, Cetuximab, enhances the in situ vaccine effect of radiation in immunologically cold head and neck Squamous cell carcinoma.\" 591139 (2020)","DOI":"10.3389\/fimmu.2020.591139"},{"key":"22","doi-asserted-by":"crossref","unstructured":"R-X Huang  and P-K Zhou  \"Signal Transduct Targeted Ther.\"  5, \"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer.\" 60 (2020)","DOI":"10.1038\/s41392-020-0150-x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"T Oike, H Ogiwara, K Torikai, et al.  \"Int J Radiat Oncol Biol Phys.\"  84, \"Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining.\" 815 (2012)","DOI":"10.1016\/j.ijrobp.2012.01.017"},{"key":"25","doi-asserted-by":"crossref","unstructured":"DR Ranoa, AD Parekh, SP Pitroda, et al.  \"Oncotarget.\"  7, \"Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.\" 26496 (2016)","DOI":"10.18632\/oncotarget.8420"},{"key":"29","doi-asserted-by":"crossref","unstructured":"MM Wattenberg, A Fahim, MM Ahmed, et al.  \"Radiat Res.\"  182, \"Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy.\" 126 (2014)","DOI":"10.1667\/RR13374.1"},{"key":"30","doi-asserted-by":"crossref","unstructured":"EA Reits, JW Hodge, CA Herberts, et al.  \"J Exp Med.\"  203, \"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.\" 1259 (2006)","DOI":"10.1084\/jem.20052494"},{"key":"31","doi-asserted-by":"crossref","unstructured":"EA Reap, K Roof, K Maynor, et al.  \"Proc Natl Acad Sci U S A.\"  94, \"Radiation and stress-induced apoptosis: a role for Fas\/Fas ligand interactions.\" 5750 (1997)","DOI":"10.1073\/pnas.94.11.5750"},{"key":"32","doi-asserted-by":"crossref","unstructured":"MA Sheard, B Vojtesek, L Janakova, et al.  \"Int J Cancer.\"  73, \"Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation.\" 757 (1997)","DOI":"10.1002\/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Y Zhang, RN Sriramaneni, PA Clark, et al.  \"Nat Commun.\"  13, \"Multifunctional nanoparticle potentiates the in situ vaccination effect of radiation therapy and enhances response to immune checkpoint blockade.\" 4948 (2022)","DOI":"10.1038\/s41467-022-32645-x"},{"key":"34","unstructured":"FG Herrera, C Ronet, M Ochoa de Olza, et al.  \"Cancer Discov.\"  12, \"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy.\" 108 (2022)"},{"key":"35","doi-asserted-by":"crossref","unstructured":"FG Herrera, P Romero, G Coukos,  \"Trends Immunol.\"  43, \"Lighting up the tumor fire with low-dose irradiation.\" 173 (2022)","DOI":"10.1016\/j.it.2022.01.006"},{"key":"36","doi-asserted-by":"crossref","unstructured":"RB Patel, R Hernandez, P Carlson, et al.  \"Sci Transl Med.\"  13, \"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade.\" (2021)","DOI":"10.1126\/scitranslmed.abb3631"},{"key":"37","doi-asserted-by":"crossref","unstructured":"JC Jagodinsky, JM Vera, WJ Jin, et al.  \"Sci Transl Med.\"  16, \"Intratumoral radiation dose heterogeneity augments antitumor immunity in mice and primes responses to checkpoint blockade.\" eadk0642 (2024)","DOI":"10.1126\/scitranslmed.adk0642"},{"key":"38","doi-asserted-by":"crossref","unstructured":"F Li, C Li, X Cai, et al.  \"EClinicalMedicine.\"  41, \"The association between CD8+ tumor-infiltrating lymphocytes and the clinical outcome of cancer immunotherapy: A systematic review and meta-analysis.\" 101134 (2021)","DOI":"10.1016\/j.eclinm.2021.101134"},{"key":"39","doi-asserted-by":"crossref","unstructured":"RA Watson, O Tong, R Cooper, et al.  \"Sci Immunol.\"  6, \"Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8(+) T cell clone size and cytotoxicity.\" eabj8825 (2021)","DOI":"10.1126\/sciimmunol.abj8825"},{"key":"13","doi-asserted-by":"crossref","unstructured":"AN Blackford  and SP Jackson  \"Mol Cell.\"  66, \"ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response.\" 801 (2017)","DOI":"10.1016\/j.molcel.2017.05.015"},{"key":"28","doi-asserted-by":"crossref","unstructured":"L Deng, H Liang, M Xu, et al.  \"Immunity.\"  41, \"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors.\" 843 (2014)","DOI":"10.1016\/j.immuni.2014.10.019"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Y Ziv, D Bielopolski, Y Galanty, et al.  \"Nat Cell Biol.\"  8, \"Chromatin relaxation in response to DNA double-strand breaks is modulated by a novel ATM- and KAP-1 dependent pathway.\" 870 (2006)","DOI":"10.1038\/ncb1446"},{"key":"27","doi-asserted-by":"crossref","unstructured":"L Deng, H Liang, B Burnette, et al.  \"Oncoimmunology.\"  3, \"Radiation and anti-PD-L1 antibody combinatorial therapy induces T cell-mediated depletion of myeloid-derived suppressor cells and tumor regression.\" e28499 (2014)","DOI":"10.4161\/onci.28499"},{"key":"1","doi-asserted-by":"crossref","unstructured":"R Baskar, KA Lee, R Yeo, et al.  \"Int J Med Sci.\"  9, \"Cancer and radiation therapy: current advances and future directions.\" 193 (2012)","DOI":"10.7150\/ijms.3635"},{"key":"20","doi-asserted-by":"crossref","unstructured":"ZS Morris, EI Guy, DM Francis, et al.  \"Cancer Res.\"  76, \"In situ tumor vaccination by combining local radiation and tumor-specific antibody or immunocytokine treatments.\" 3929 (2016)","DOI":"10.1158\/0008-5472.CAN-15-2644"},{"key":"17","doi-asserted-by":"crossref","unstructured":"AE Besemer, YM Yang, JJ Grudzinski, et al.  \"Cancer Biother Radiopharm.\"  33, \"Development and validation of RAPID: A patient-specific Monte Carlo three-dimensional internal dosimetry platform.\" 155 (2018)","DOI":"10.1089\/cbr.2018.2451"},{"key":"26","doi-asserted-by":"crossref","unstructured":"LR Werner, JS Kler, MM Gressett, et al.  \"Radiother Oncol.\"  124, \"Transcriptional-mediated effects of radiation on the expression of immune susceptibility markers in melanoma.\" 418 (2017)","DOI":"10.1016\/j.radonc.2017.08.016"}],"container-title":["Radiation Research"],"original-title":[],"link":[{"URL":"https:\/\/radiation-research.kglmeridian.com\/view\/journals\/rare\/aop\/article-10.1667-RADE-25-00203.1\/article-10.1667-RADE-25-00203.1.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/radiation-research.kglmeridian.com\/downloadpdf\/journals\/rare\/aop\/article-10.1667-RADE-25-00203.1\/article-10.1667-RADE-25-00203.1.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/radiation-research.kglmeridian.com\/downloadpdf\/journals\/rare\/aop\/article-10.1667-RADE-25-00203.1\/article-10.1667-RADE-25-00203.1.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:08:23Z","timestamp":1791234503000},"score":1,"resource":{"primary":{"URL":"https:\/\/bioone.org\/journals\/radiation-research\/volume-205\/issue-5\/RADE-25-00203.1\/Enhanced-Response-to-Radiopharmaceutical-Therapy-in-Preclinical-Tumor-Models-with\/10.1667\/RADE-25-00203.1.full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1667\/rade-25-00203.1","relation":{},"ISSN":["0033-7587","1938-5404"],"issn-type":[{"value":"0033-7587","type":"print"},{"value":"1938-5404","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]}}}